Special Issue "Marine Immunomodulatory Compounds"

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: 15 March 2024 | Viewed by 1401

Special Issue Editors

Istituto di Chimica Biomolecolare del CNR, Via Campi Flegrei 34, 80078 Pozzuoli, Napoli, Italy
Interests: medicinal chemistry; organic chemistry; chemical biology; algae culture; secondary metabolites; diatoms; methods; terpenoids; immunology and microbiology
Special Issues, Collections and Topics in MDPI journals
Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Via Campi Flegrei 34, 80078 Pozzuoli, Italy
Interests: immunology; natural product drug discovery; cell biology; inflammation; microalgae
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The last decade has included significant successes in understanding how the human immune system can be manipulated to fight cancer. In this context, the cells of the innate immune system, namely those specialized in antigen presentation and phagocytosis, have been recognized as active players in immunotherapy. The activation of dendritic cells, macrphages and microglia is the result of the binding of signal molecules to a Pattern Recognition Receptor (PRRs) and other immune receptors. Toll-like receptors (TLRs) are one of the best characterized families of pattern recognition receptors (PRRs) and play a critical role in the host defense to infection. However, a new class of receptors with immunomodulatory activity are involved in the activation and survival of myeloid cells, whose endogenous ligands and mechanisms of action are still poorly investigated. Among these, C-type lectin and immunoglobulin-like receptors play an important role in the innate immunity regulation.

In this field, the potential anticancer and immunological activity of natural products represent an excellent and unexplored source for the development of new drugs. Marine natural products are a unique rich source of new metabolites, with diverse chemical structures and molecular features adapted to specific interactions with cellular targets.

This Special Issue will cover all fields of research and development of marine natural products in chemical immunology. The volume includes studies on in vitro and/or in vivo activity on receptors of the innate immune system, isolation and structure characterization of natural immunomdoulators, mechanisms of action, therapeutic applications, and synthetic approaches for the preparation of active compounds and functional analogues.

Prof. Dr. Angelo Fontana
Dr. Carmela Gallo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • chemical immunology
  • marine natural product
  • immunomodulation
  • innate immune receptor
  • bioactive compound
  • immunotherapy
  • natural products bioassay
  • isolation
  • structure elucidation
  • organic synthesis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


19 pages, 10468 KiB  
New Insights into the Mechanism of Ulva pertusa on Colitis in Mice: Modulation of the Pain and Immune System
Mar. Drugs 2023, 21(5), 298; https://doi.org/10.3390/md21050298 - 13 May 2023
Cited by 2 | Viewed by 1181
Inflammatory bowel diseases (IBDs) involving Crohn’s disease (CD) and ulcerative colitis (UC) are gastrointestinal (GI) disorders in which abdominal pain, discomfort, and diarrhea are the major symptoms. The immune system plays an important role in the pathogenesis of IBD and, as indicated by [...] Read more.
Inflammatory bowel diseases (IBDs) involving Crohn’s disease (CD) and ulcerative colitis (UC) are gastrointestinal (GI) disorders in which abdominal pain, discomfort, and diarrhea are the major symptoms. The immune system plays an important role in the pathogenesis of IBD and, as indicated by several clinical studies, both innate and adaptative immune response has the faculty to induce gut inflammation in UC patients. An inappropriate mucosal immune response to normal intestinal constituents is a main feature of UC, thus leading to an imbalance in local pro- and anti-inflammatory species. Ulva pertusa, a marine green alga, is known for its important biological properties, which could represent a source of beneficial effects in various human pathologies. We have already demonstrated the anti-inflammatory, antioxidant, and antiapoptotic effects of an Ulva pertusa extract in a murine model of colitis. In this study, we aimed to examine thoroughly Ulva pertusa immunomodulatory and pain-relieving properties. Colitis was induced by using the DNBS model (4 mg in 100 μL of 50% ethanol), whereas Ulva pertusa was administered daily at the dosage of 50 and 100 mg/kg by oral gavage. Ulva pertusa treatments have been shown to relieve abdominal pain while modulating innate and adaptative immune-inflammatory responses. This powerful immunomodulatory activity was specifically linked with TLR4 and NLRP3 inflammasome modulation. In conclusion, our data suggest Ulva pertusa as a valid approach to counteract immune dysregulation and abdominal discomfort in IBD. Full article
(This article belongs to the Special Issue Marine Immunomodulatory Compounds)
Show Figures

Figure 1

Back to TopTop